Published in Recent Results Cancer Res on January 01, 2003
Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer (2007) 3.77
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev (2015) 2.51
Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol (2008) 1.17
Regulation of multiple insulin-like growth factor binding protein genes by 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res (2005) 1.10
Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther (2007) 1.09
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila) (2011) 0.87
Cyclical regulation of the insulin-like growth factor binding protein 3 gene in response to 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res (2010) 0.84
Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle (2008) 0.83
GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells. Endocrinology (2010) 0.80
Solar radiation and the incidence and mortality of leading invasive cancers in the United States. Dermatoendocrinol (2016) 0.77
Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D₂ Against Human Malignant Melanoma Cell Lines. Int J Mol Sci (2016) 0.76
Vitamin D derivatives enhance cytotoxic effects of H2O2 or cisplatin on human keratinocytes. Steroids (2016) 0.75
The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study. World J Urol (2013) 0.75
Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med (2009) 12.77
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Hypertension: which drugs to choose for patients with cardiovascular disease. J Fam Pract (2006) 2.05
Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol (2011) 1.97
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev (2009) 1.76
Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate (2006) 1.76
Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev (2004) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Cardiomyopathy: an overview. Am Fam Physician (2009) 1.68
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol (2005) 1.63
Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer (2004) 1.61
Stable patients on left ventricular assist device support have a disproportionate advantage: time to re-evaluate the current UNOS policy. J Heart Lung Transplant (2011) 1.58
Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol (2012) 1.58
Management of unstable/acute slipped capital femoral epiphysis: results of a survey of the POSNA membership. J Pediatr Orthop (2005) 1.57
Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am (2010) 1.53
Australia's drought: lessons for California. Science (2014) 1.48
Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat (2003) 1.47
Rethinking the terminology of mechanical circulatory support. J Thorac Cardiovasc Surg (2012) 1.47
Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res (2002) 1.43
Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J Urol (2005) 1.42
Operative treatment of tibial fractures in children: are elastic stable intramedullary nails an improvement over external fixation? J Bone Joint Surg Am (2005) 1.39
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol (2006) 1.38
Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate (2009) 1.37
The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am (2010) 1.37
Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology (2003) 1.35
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A (2007) 1.30
Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res (2006) 1.28
Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol (2004) 1.28
Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology (2006) 1.27
Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res (2005) 1.27
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem (2003) 1.25
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene (2004) 1.20
Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology (2009) 1.19
Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis (2006) 1.17
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate (2004) 1.17
Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol (2010) 1.16
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer (2003) 1.15
The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol (2011) 1.15
Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J Steroid Biochem Mol Biol (2005) 1.14
Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling. J Steroid Biochem Mol Biol (2010) 1.13
Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol (2004) 1.13
A novel mutation in helix 12 of the vitamin D receptor impairs coactivator interaction and causes hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Mol Endocrinol (2002) 1.09
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol (2011) 1.08
Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer (2010) 1.08
Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol (2005) 1.05
The timing for transplantation superior genetics or social prejudice? J Am Coll Cardiol (2006) 1.05
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res (2012) 1.04
Interactions of the vitamin D receptor with the corepressor hairless: analysis of hairless mutants in atrichia with papular lesions. J Biol Chem (2007) 1.04
CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res (2004) 1.03
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol (2007) 1.03
Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol (2007) 1.02
Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol (2004) 1.02
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm (2010) 1.01
Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology (2004) 1.01
Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology (2012) 1.00
Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia resulting from a novel missense mutation in the DNA-binding domain of the vitamin D receptor. Mol Genet Metab (2010) 1.00
Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A (2009) 1.00
The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids (2012) 0.98
A unique insertion/duplication in the VDR gene that truncates the VDR causing hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Arch Biochem Biophys (2006) 0.98
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther (2006) 0.98
Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Endocrinology (2008) 0.97
Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). Cancer Causes Control (2006) 0.97
Barriers to blood pressure control as reported by African American patients. J Natl Med Assoc (2009) 0.97
Russell body duodenitis: a histopathological and molecular approach to a rare clinical entity. Pathol Res Pract (2012) 0.97
Physician reported perception in the treatment of high blood pressure does not correspond to practice. BMC Fam Pract (2009) 0.97
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med (2005) 0.97
Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res (2008) 0.96
Adapting urban water systems to a changing climate: lessons from the millennium drought in southeast Australia. Environ Sci Technol (2013) 0.96
Relations between obesity, insulin resistance, and 25-hydroxyvitamin D. Am J Clin Nutr (2012) 0.96
Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol (2002) 0.95
Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation. Prostate (2009) 0.95
Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther (2006) 0.95
Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res (2007) 0.94
Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate (2003) 0.94
The role of vitamin D and SLCO1B1*5 gene polymorphism in statin-associated myalgias. Dermatoendocrinol (2010) 0.94
A unique insertion/substitution in helix H1 of the vitamin D receptor ligand binding domain in a patient with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Bone Miner Res (2004) 0.94
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res (2002) 0.93
Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol (2002) 0.93
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology (2002) 0.92
Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr (2007) 0.91
Adoption of exercise and readiness to change differ between Whites and African-Americans with hypertension: a report from the Ohio State University Primary Care Practice-Based Research Network (OSU-PCPBRN). J Am Board Fam Med (2008) 0.91
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol (2003) 0.91